AEON Biopharma Strengthens ABP-450's Molecular Similarity to BOTOX® with Expanded Structural Data
Event summary
- AEON Biopharma achieved 98% sequence coverage of the active botulinum neurotoxin in ABP-450, with 100% amino acid identity across all regions analyzed.
- Preliminary analysis confirmed the same critical disulfide bond (C430-C454) connecting the light and heavy chains in both ABP-450 and BOTOX®.
- The expanded primary structure analysis was performed across six drug product samples encompassing both ABP-450 and BOTOX®.
- AEON expects feedback from its planned BPD Type 2b interaction with the FDA in the second half of 2026 to inform the next phase of ABP-450 development.
The big picture
AEON Biopharma's expanded structural data supporting the molecular similarity of ABP-450 to BOTOX® is a critical step in its quest for full-label U.S. market entry. The $3.0 billion annual therapeutic neurotoxin market represents a significant opportunity for biosimilar entry, and AEON's progress in building the foundational molecular identity package for ABP-450 increases its confidence as it navigates the regulatory pathway. The consistency of these findings across multiple samples and lots underscores the potential for ABP-450 to achieve biosimilarity to BOTOX®, which could lead to accelerated market access and significant revenue potential.
What we're watching
- Regulatory Feedback
- How the FDA's feedback from the planned BPD Type 2b interaction will shape the next phase of ABP-450 development, including clinical pharmacology and comparative clinical study requirements.
- Molecular Similarity
- Whether AEON can sustain the molecular similarity of ABP-450 to BOTOX® through further analytical and clinical testing.
- Market Entry
- The pace at which AEON can achieve full-label U.S. market entry for ABP-450, given the scientific challenges associated with characterizing a 900 kDa botulinum neurotoxin complex.